Andreessen Marc L's Form 4 filing
Camp4 Therapeutics CorpCAMP · filed Oct 17, 2024
- Accession no.
- 0001415889-24-025380
- Filed
- Oct 17, 2024, 5:05 PM ET
- Trade date
- Oct 15, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $8.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Andreessen Marc LCIK 0001160077 | 10% Owner |
| Horowitz Benjamin ACIK 0001166586 | 10% Owner |
| AH Equity Partners Bio I, L.L.C.CIK 0001656626 | 10% Owner |
| AH Bio Fund I, L.P.CIK 0001656629 | 10% Owner |
| AH Bio Fund IV, L.P.CIK 0001889476 | 10% Owner |
| AH Equity Partners Bio IV, L.L.C.CIK 0001889898 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 15, 2024 | Common Stock | CConversionAcquired | +1,398,067 | –F1 | – | 1,398,067 | Indirect | |
| Oct 15, 2024 | Common Stock | PPurchaseAcquired | +181,818 | $11.00 | +$1,999,998 | 1,579,885 | Indirect | |
| Oct 15, 2024 | Common Stock | PPurchaseAcquired | +545,454 | $11.00 | +$5,999,994 | 545,454 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
Referenced by the price of 1 transaction in Table I and 2 transactions in Table II.